10-K: Centessa Pharmaceuticals Reports Full Year 2023 Results, Highlights Pipeline Progress

Centessa Pharmaceuticals' 2023 annual report details financial results, pipeline advancements, and strategic shifts, including progress in hemophilia and sleep disorder programs.

Summary

• Centessa Pharmaceuticals, a clinical-stage company, released its full year 2023 results, emphasizing its mission to develop transformational medicines.
• The company is advancing SerpinPC for hemophilia, with registrational studies PRESent-2 and PRESent-3 initiated in July and October 2023, respectively.
• ORX750, an oral OX2R agonist for sleep disorders, is progressing towards clinical development with proof-of-concept data expected in 2024.
• The LockBody technology platform, featuring LB101 for solid tumors, is in a Phase 1/2a clinical trial, with the first subject dosed in March 2023.
• Centessa has deprioritized certain programs, including CBS001, CBS004, and MGX292, and out-licensed CBS004 to AnaptysBio, Inc.
• The company reported a net loss of $151.1 million for 2023, compared to a net loss of $216.2 million in 2022.
• As of December 31, 2023, Centessa had $256.5 million in cash, cash equivalents, and short-term investments, expected to fund operations into 2026 without drawing on the remaining available tranches under the Oberland Capital financing agreement.
• The company is subject to a credit facility with Oberland Capital, which includes financial covenants and potential acceleration clauses.
• The global hemophilia market was estimated to be over $12 billion as of 2023.
• Revenue associated with oxybate products indicated for narcolepsy and IH was approximately $2 billion in 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in the pipeline and a clear strategy, the company is still in the early stages of development, faces significant risks, and is not yet profitable. The financial results are worse than the previous year, and there are potential delays in clinical trials. The company is also reliant on third parties for manufacturing and clinical trials. The sentiment is therefore neutral to slightly negative.

Positives

• SerpinPC has shown a favorable safety and tolerability profile, as well as evidence of sustained reduction in all-bleeds annualized bleed rates (ABRs).
• ORX750 preclinical data showed it is a highly potent and selective orexin agonist that closely mimics the function of the endogenous peptide.
• LB101 has shown significantly improved tumor regression and survival compared to anti-PD-L1 antibodies in a syngeneic mouse model.
• The company has a streamlined, integrated registrational development plan for SerpinPC in hemophilia B with fewer than 200 total subjects.
• The company has a track record of making judicious capital and resource allocation decisions for discovery and development efforts across its portfolio.

Negatives

• The company has incurred net losses since inception and expects to continue to incur losses for the foreseeable future.
• The company is dependent on third-party contract development and manufacturing organizations (CDMOs) for all of its requirements of raw materials, drug substance and drug product.
• The company faces challenges, risks and expenses related to the integration of the operations of its Centessa Subsidiaries.
• The company's credit facility and payment obligations under the Note Purchase Agreement with Oberland Capital contain operating and financial covenants that restrict its business and financing activities.

Risks

• The company may not be successful in its efforts to use its differentiated asset-centric drug discovery and development approach.
• A single or limited number of programs or product candidates may comprise a large proportion of the company's value.
• The company faces challenges, risks and expenses related to the integration of the operations of its Centessa Subsidiaries.
• The company will need substantial additional funds to advance development of its product candidates.
• The company's credit facility and payment obligations under the Note Purchase Agreement with Oberland Capital contain operating and financial covenants that restrict its business and financing activities.
• The company's product candidates are in various stages of development and may fail or suffer delays.
• The company may not be successful in its efforts to identify, discover, in-license or otherwise acquire additional product candidates.
• The company may encounter substantial delays or challenges in the initiation, conduct or completion of its clinical trials.
• The company may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize its product candidates.
• The company relies on third parties to conduct its preclinical studies, clinical trials, and manufacturing activities.
• The company could experience manufacturing problems that result in delays or other material disruptions.
• Business interruptions resulting from the Russia-Ukraine war and Israel-Hamas conflict could cause a disruption in the development of the company's product candidates.
• The company may not be able to obtain and maintain sufficient patent and other intellectual property protection.
• The company has never commercialized a product candidate and may lack the necessary expertise, personnel and resources to successfully commercialize any of its products.
• The company's international operations may expose it to business, regulatory, legal, political, operational, financial, pricing and reimbursement risks.
• The company is an emerging growth company and a smaller reporting company, and the reduced reporting requirements may make its ADSs less attractive to investors.
• The company previously had material weaknesses in its internal control systems over financial reporting, which have been remediated, but may identify new material weaknesses in the future.
• Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.
• There is uncertainty as to whether the company is or will be a passive foreign investment company (PFIC), which could have material adverse U.S. federal income tax consequences to U.S. holders.

Future Outlook

The company plans to advance ORX750 into clinical development with the goal of sharing clinical proof-of-concept data in sleep-deprived healthy volunteers in 2024. The company expects its cash, cash equivalents and short-term investments to fund its operations into 2026 without drawing on the remaining available tranches under the Oberland Capital financing agreement.

Management Comments

• The company is focused on developing high conviction programs with differentiated mechanisms of action.
• The company is executing a near-term strategy focused on advancing the late-stage development of SerpinPC, advancing the OX2R agonist program, and strategically investing in the LockBody technology platform.
• The company has a track record of making judicious capital and resource allocation decisions for discovery and development efforts across its portfolio, and expeditiously evaluating and terminating programs when the data do not support advancement.

Industry Context

The document highlights the competitive landscape in hemophilia, sleep disorders, and oncology, noting the presence of major pharmaceutical and biotechnology companies, as well as emerging players. The company is positioning its product candidates as potential best-in-class therapies with differentiated mechanisms of action.

Comparison to Industry Standards

• The company's SerpinPC program is competing with existing factor replacement therapies, emicizumab, and gene therapies in the hemophilia market, which is estimated to be over $12 billion.
• The company's ORX750 program is competing with existing treatments for narcolepsy and idiopathic hypersomnia, including oxybate products, which generated approximately $2 billion in revenue in 2023.
• The company's LB101 program is competing with other CD47 and PD-L1 targeted therapies in the solid tumor market, including those from ALX Oncology, Light Chain Bioscience, and Innovent Biologics.
• The company's approach to drug discovery and development is differentiated by its asset-centric model, which focuses on high conviction programs with novel mechanisms of action.

Legal Proceedings

• The company and certain of its current and former officers were named as defendants in a proposed class-action lawsuit alleging materially false and/or misleading statements relating to the safety profile and future clinical and commercial prospects of its lixivaptan and ZF874 programs.

Related Party Transactions

• The company has entered into Master Services agreements with certain drug discovery companies affiliated with David Grainger, former Chief Innovation Officer.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by changes in compensation or benefits.
• Patients may benefit from the development of new therapies.
• Suppliers and creditors may be affected by the company's financial performance.

Next Steps

• Advance the late-stage development of SerpinPC in hemophilia.
• Advance the OX2R agonist program with clinical development of ORX750.
• Strategically invest in and advance the LockBody technology platform with LB101.
• Evaluate opportunities to accelerate development timelines and enhance commercial potential of programs in collaboration with third parties.

Key Dates

Keywords

Hemophilia, SerpinPC, Orexin Receptor 2, OX2R Agonist, ORX750, LockBody Technology, LB101, Clinical Trials, Pharmaceuticals, Biotechnology, Drug Development, Regulatory Approval, Sleep Disorders, Solid Tumors